Ironwood Pharmaceuticals (IRWD) Non-Current Deffered Revenue (2010 - 2018)

Ironwood Pharmaceuticals has disclosed Non-Current Deffered Revenue across 9 years of filings, most recently posting $6.3 million for Q4 2018.

• Non-Current Deffered Revenue for Q4 2018 came in at $6.3 million, up 15.76% year-over-year; the trailing twelve-month figure through Dec 2018 was $6.3 million (up 15.76% YoY), and the FY2018 annual result was $6.3 million, up 15.76% from the prior year.
• Non-Current Deffered Revenue came in at $6.3 million for Q4 2018 at Ironwood Pharmaceuticals, up from $6.1 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $10.5 million in Q4 2014 to a low of $557000.0 in Q4 2016.
• The 5-year median for Non-Current Deffered Revenue is $6.0 million (2018), against an average of $5.6 million.
• Across the five-year window, Non-Current Deffered Revenue tumbled 91.29% in 2016 and jumped 878.28% in 2017, its largest moves.
• Ironwood Pharmaceuticals' Non-Current Deffered Revenue stood at $10.5 million in 2014, then slumped by 39.22% to $6.4 million in 2015, then sank by 91.29% to $557000.0 in 2016, then surged by 878.28% to $5.4 million in 2017, then climbed by 15.76% to $6.3 million in 2018.
• The last three Non-Current Deffered Revenue figures came in at $6.3 million (Q4 2018), $6.1 million (Q3 2018), and $6.1 million (Q2 2018), per Business Quant data.